CD274 and neoplasm: Similar results for anti‐PD1/anti‐PD‐L1 treatment have also been found in recent studies.34, 38 Considering that tTMB (tumor mutational burden) is a good measure of overall neo‐antigen load, along with the positive correlation between tTMB and bTMB34 and the easy availability of blood biopsies, it is assumed that baseline bTMB would be a better outcome predictor than tTMB in the future clinical practice.